Summit Place Financial Advisors LLC Reduces Holdings in Zoetis Inc. $ZTS

Summit Place Financial Advisors LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 41.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 11,261 shares of the company’s stock after selling 8,108 shares during the period. Summit Place Financial Advisors LLC’s holdings in Zoetis were worth $1,417,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Oppenheimer & Co. Inc. lifted its holdings in shares of Zoetis by 15.1% during the fourth quarter. Oppenheimer & Co. Inc. now owns 104,946 shares of the company’s stock worth $13,204,000 after purchasing an additional 13,764 shares during the period. Secured Retirement Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth about $844,000. Sigma Planning Corp lifted its holdings in shares of Zoetis by 3.8% during the fourth quarter. Sigma Planning Corp now owns 3,401 shares of the company’s stock worth $424,000 after purchasing an additional 124 shares during the period. Laurel Wealth Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth about $50,000. Finally, Verity Asset Management Inc. lifted its holdings in shares of Zoetis by 11.5% during the fourth quarter. Verity Asset Management Inc. now owns 2,634 shares of the company’s stock worth $331,000 after purchasing an additional 271 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.1%

Shares of NYSE:ZTS opened at $115.10 on Friday. Zoetis Inc. has a 12-month low of $112.97 and a 12-month high of $172.23. The company has a market capitalization of $48.42 billion, a PE ratio of 19.12, a PEG ratio of 1.75 and a beta of 0.98. The business has a 50 day moving average of $119.93 and a two-hundred day moving average of $124.79. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the previous year, the company posted $1.40 earnings per share. Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts forecast that Zoetis Inc. will post 7.02 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

A number of research firms recently commented on ZTS. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $151.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.